CombiChem Squeezes Through a Narrow Exit Door
Executive Summary
CombiChem's acquisition by DuPont deal is, somewhat paradoxically, yet further proof of the difficulty that early-stage biotechs will have in finding Big Pharma buyers. Unless discovery biotechs are offering something specifically appropriate to a particular drug firm, even moderately valued acquisitions are unlikely exit opportunities.
You may also be interested in...
Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.
Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing
Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.
US FDA, Industry Prepare For Potential Spread Of Surging Demand For Children’s Pain Relief OTCs
FDA “understands that manufacturers expect availability to continue to increase in the near future.” CHPA is working with members “focused on safeguarding the US supply by maximizing capacity to produce and direct product to where it is needed most.”